Voyager Therapeutics, which is developing treatments for central nervous system diseases, has raised $124m from investors including Aventis.
Voyager Therapeutics, a US-based gene therapy technology developer backed by pharmaceutical firm Sanofi through its Aventis subsidiary, filed for an $86.3m initial public offering on Friday.
Founded in 2013, Voyager is working on gene therapy treatments for diseases affecting the central nervous system. Its most advanced clinical candidate, VY-AADC01, is currently in an open-label, Phase 1b clinical trial for advanced Parkinson’s disease.
The company intends to use the IPO proceeds to fund further clinical development and manufacturing of VY-AADC01,…
